Public Release: 

Insilico Medicine to present deep learned biomarkers at the Deep Learning in Healthcare Summit

Insilico Medicine to present a range of deep learned biomarkers of ageing and deep learned predictors of biological age at the RE-WORK Deep learning in Healthcare Summit

InSilico Medicine, Inc.

Baltimore, MD - Alex Zhavoronkov, PhD, CEO of Insilico Medicine will present a range of deep learned biomarkers of ageing and deep learned predictors of biological age at the RE-WORK Deep Learning in Healthcare Summit in London, 7-8th of April. The first such predictor is already available online at http://www.Aging.AI trained on hundreds of thousands of human biochemistry and cell count samples linked to chronological age, gender and health status. Transcriptomic and signalomic ageing markers and predictors of chronological and biological age and cross-species comparison will be discussed. The official summit website is https://www.re-work.co/events/deep-learning-health-london-2016 .

"RE-WORK summits are clearly outperforming most industry conferences in agility, openness, diversity and focus on applications of deep learning in multiple areas and we are happy to be invited to present at their Deep Learning in Healthcare Summit in London. Artificial intelligence will transform biomarker development and drug discovery much sooner than most pharmaceutical companies and regulators expect and we are happy to be at the forefront of this emerging trend", said Alex Zhavoronkov, PhD, CEO or Insilico Medicine, Inc.

The Pharmaceutical Artificial Intelligence division of Insilico Medicine is providing a broad range of machine learning services in biomarker development, drug discovery and high-throughput screening optimization to some of the most innovative pharmaceutical and biotechnology companies. In 2015 scientists at Insilico Medicine published over 20 research papers in reputable academic journals.

"While our main project is related to applying artificial intelligence to identify and personalize Geroprotectors, interventions that slow down or reverse human biological aging, we have a solid pipeline of pharma and biotechnology research projects that help us fund our own research, gain unique expertise and establish reputation as a trusted partner. If you are reading this, please follow us on PubMed or ResearchGate and consider collaborating with our team and please attend our conferences in St. Petersburg and Basel", said Alex Aliper, president of Insilico Medicine, Inc.

###

About Insilico Medicine, Inc

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery and provides services to pharmaceutical companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.